Next revolution in molecular theranostics: Personalized medicine for urologic cancers

Future Oncology

Volumn 11, Issue 15, 2015, Pages 2205-2219

  Aoun, Fouad ^a,b   Kourie, Hampig Raphael ^a,b   Artigas, Carlos ^a,b   Roumeguère, Thierry ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

bombesin; carbonic anhydrase; kidney cancer; neurotensin; prostate cancer; PSMA; theranostics

Indexed keywords

BOMBESIN; CARBONATE DEHYDRATASE IX; NEUROPEPTIDE RECEPTOR; NEUROTENSIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

BLADDER CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; HUMAN; HYPOXIA; KIDNEY CARCINOMA; MOLECULAR DIAGNOSTICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; URINARY TRACT CANCER; GENETICS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; THERANOSTIC NANOMEDICINE; URINARY BLADDER NEOPLASMS;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; CARBONIC ANHYDRASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; KIDNEY NEOPLASMS; MALE; PRECISION MEDICINE; PROSTATIC NEOPLASMS; RECEPTORS, NEUROPEPTIDE; THERANOSTIC NANOMEDICINE; URINARY BLADDER NEOPLASMS;

EID: 84938537050     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.104     Document Type: Review

References (124)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011
2. Steliarova-Foucher E, Stiller C, Kaatsch P et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCIS project): An epidemiological study. Lancet 364(9451), 2097-2105 (2004
3. Sudhakar A. History of cancer, ancient and modern treatment methods. J. Cancer Sci. Ther. 1(2), 1-4 (2009
4. Hamburg M, Collins F. The path to personalized medicine. N. Engl J. Med. 363, 301-304 (2010
5. Netto G. Molecular diagnostics in urologic malignancies: A work in progress. Arch. Pathol. Lab. Med. 135(5), 610-621 (2011
6. Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Crit. Care Med. 37(1), 50-58 (2009
7. Mendelsohn J. Personalizing oncology: perspectives and prospects. J. Clin. Oncol. 31(15), 1904-1911 (2013
8. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug. Chem. 22, 1879-1903 (2011)
9. Nicolaides NC, O'Shannessy DJ, Albone E, Grasso L. Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy. Front Oncol. 13(4), 141-155 (2014
10. Idée JM, Louguet S, Ballet S, Corot C. Theranostics and contrast-agents for medical imaging: A pharmaceutical company viewpoint. Quant. Imaging Med. Surg. 3(6), 292-297 (2013
11. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11(3), 220-228 (2010
12. Bradley WG, Golding SG, Herold CJ et al. Globalization of P4 medicine: predictive, personalized, preemptive, and participatory - summary of the proceedings of the Eighth International Symposium of the International Society for Strategic Studies in Radiology, 2009. Radiology 258(2), 571-582 (2011
13. Omidi Y, Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bio Impacts 4(2), 55-67 (2014
14. Ilardi G, Zambrano N, Merolla F et al. Histopathological determinants of tumor resistance: A special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers. Curr. Med. Chem. 21(14), 1569-1582 (2014
15. Sedlakova O, Svastova E, Takacova M, Kopacek J, Pastorek J, Pastorekova S. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front. Physiol. 4, 400-414 (2013
16. Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin. Cancer Biol. 18(5), 330-337 (2008
17. Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33, 480-487 (1996
18. Pastorek J, Pastorekova S, Callebaut I et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9, 2877-2888 (1994
19. Grabmaier K, Vissers JL, De Weijert MC et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 85, 865-870 (2000
20. Pastorekova S, Parkkila S, Parkkila AK et al. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112, 398-408 (1997
21. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE et al. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. AntiCancer Res. 19, 1197-1200 (1999
22. Saarnio J, Parkkila S, Parkkila AK et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J. Histochem. Cytochem. 46, 497-504 (1998
23. Karhumaa P, Kaunisto K, Parkkila S et al. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol. Hum. Reprod. 7, 611-616 (2001
24. Kivela AJ, Parkkila S, Saarnio J et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem. Cell Biol. 114, 197-204 (2000
25. Patard JJ, Fergelot P, Karakiewicz P et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 123(2), 395-400 (2008
26. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?. Biochim. Biophys. Acta. 1795, 162-172 (2009
27. Chan D, Sutphin P, Yen SR, Giaccia A. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1α. Mol. Cell. Biol. 5(15), 6415-6426 (2005
28. Grabmaier K, Weijert MC AD, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX (G250/MN) by HIF-1 alpha in clear cell renal cell carcinoma. Oncogene 23, 5624-5631 (2004
29. Bismar TA, Bianco FJ, Zhang H et al. Quantification of G250 Mrna expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Pathology 35, 513-517 (2003
30. De Martino M, Klatte T, Seligson DB et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J. Urol. 82, 728-734 (2009
31. McDermott DF, Cheng SC, Signoretti S et al. The high-dose aldesleukin "select" trial: A trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 21(3), 561-568 (2015
32. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004
33. Cho D, Signoretti S, Dabora S et al. Potential histologic andmolecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5, 379-385 (2007
34. Phuoc NB, Ehara H, Gotoh T et al. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol. Rep. 20(3), 525-530 (2008
35. Zhou GX, Ireland J, Rayman P, Finke J, Zhou M. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology 75(2), 257-221 (2010
36. Kim HL, Seligson D, Liu X et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 173, 1496-1501 (2005
37. Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10, 5464-5471 (2004
38. Steffens MG, Boerman OC, Oosterwijk-Wakka JC et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol. 15, 1529-1537 (1997
39. Steffens MG, Boerman OC, De Mulder PH et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res. 5, 3268-3274 (1999
40. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494 (1986
41. Brouwers AH, Dorr U, Lang O et al. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: A comparative study. Nucl. Med. Commun. 23, 229-236 (2002
42. Brouwers AH, Buijs WC, Oosterwijk E et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111) In: An intrapatient comparison. Clin. Cancer Res. 9, 3953-3960 (2003
43. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: A carbonic anhydrase IX monoclonal antibody. Curr. Oncol. Rep. 7(2), 109-115 (2005
44. Divgi CR, Pandit-Taskar N, Jungbluth AA et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A Phase I trial. Lancet Oncol. 8, 304-310 (2007
45. Divgi CR, Uzzo RG, Gatsonis C et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: Results from the REDECT trial. J. Clin. Oncol. 31(2), 187-194 (2013
46. Stillebroer A, Oosterwijk E, Oyen W, Mulders P, Boerman P. Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging. 7(1), 179-188 (2007
47. Davis I, Wiseman G, Fook-Thean Lee FT et al. A Phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 7, 13-21 (2007
48. Bleumer I, Knuth A, Oosterwijk E et al. A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer. 90(5), 985-990 (2004
49. Belldegrun A, Chamie K, Kloepfer P et al. ARISER: A randomized double blind Phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-results and implications for adjuvant clinical trials. J. Clin. Oncol. 31(Suppl.) Abstr 4507 (2013
50. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC et al. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J. Urol. 175(1), 57-62 (2006
51. Brouwers AH, Mulders PF, De Mulder PH et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131IcG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol. 23, 6540-6548 (2005
52. Brouwers AH, Van Eerd JE, Frielink C et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J. Nucl. Med. 45, 327-337 (2004
53. Stillebroer A, Boerman O, Desar I et al. Phase 1 radioimmunotherapy study with lutetium 177-labelled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. 64, 478-485 (2013
54. Study of Lutetium-177 Labeled cG250 in Patients With Advanced Renal Cancer. http://www.clinicaltrials.gov
55. Uemura H, Fujimoto K, Tanaka M et al. A Phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine refractory metastatic renal cell carcinoma. Clin. Cancer Res. 12, 1768-1775 (2006
56. Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin. Cancer Biol. 31, 52-64 (2015
57. Tso CL, Zisman A, Pantuck A et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/ monocyte-colony stimulating factor. Cancer Res. 61, 7925-7933 (2001
58. Hernandez JM, Bui MH, Han KR et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin. Cancer Res. 9, 1906-1916 (2003)
59. Vaccination of patients with renal cell cancer with dendritic cell tumor fusions and GM-CSF. http://www.clinicaltrials.gov
60. Bauer S, Oosterwijk-Wakka JC, Adrian N et al. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int. J. Cancer 125, 115-123 (2009
61. Hunter BA, Eustace A, Irlam JJ et al. Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer. Br. J. Cancer. 111(3), 437-443 (2014
62. Wykoff CC, Beasley NJ, Watson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60, 7075-7083 (2000)
63. Hussain SA, Palmer DH, Ganesan R et al. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol. Rep. 11(5), 1005-1010 (2004
64. Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer. 89, 1290-1297 (2003
65. Klatte T, Seligson DB, Rao JY et al. Carbonic anhydrase IX in bladder cancer: A diagnostic, prognostic, and therapeutic molecular marker. Cancer 115(7): 1448-1458 (2009
66. Turner KJ, Crew JP, Wykoff CC et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br. J. Cancer. 86, 1276-1282 (2002
67. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. AntiCancer Res. 7, 927-936 (1987
68. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding prostate-specific membrane antigen. Cancer Res. 53, 227-230 (1993
69. Bostwick DG, Pacelli A, Blute M et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: study of 184 cases. Cancer 82, 2256-2261 (1998
70. Silver DA, Pellicer I, Fair WR et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81-85 (1997
71. Wright GL Jr, Grob BM, Haley C et al. Up regulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48, 326-334 (1996
72. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl Acad. Sci. USA 93, 749-753 (1996
73. Tiffany CW, Lapidus RG, Merion A, Calvin DC, Slusher BS. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate 39, 28-35 (1999
74. Devlin AM, Ling EH, Peerson JM et al. Glutamate carboxypeptidase II: A polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum. Mol. Genet. 9, 2837-2844 (2009
75. Colombatti M, Grasso S, Porzia A et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS ONE 4(2), 4608 (2009
76. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198 (1999
77. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol. Cell Biol. 26(14), 5310-5324 (2006
78. Grant CL, Caromile LA, Ho V, Durrani K, Rahman MM, Claffey KP, Fong GH, Shapiro LH. Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS ONE 7(7), e41285 (2012
79. Yin L, Rao P, Elson P et al. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS ONE 6(6), e21319 (2011
80. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30, 232-234 (1997
81. Troyer JK, Feng Q, Beckett ML, Wright GL. Biochemical characterization and mapping of the 7E11-5.3 epitope of the prostate specific membrane antigen. Urol. Oncol. 1, 29-37 (1995
82. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ et al. In vitro characterization of radiolabeledmonoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res. 60, 5237-5243 (2000
83. Bander NH, Trabulsi EJ, Kostakoglu L et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 170, 1717-1721 (2003
84. Liu H, Rajasekaran AK, Moy P et al. Constitutive and antibody-induced internalization of prostatespecific membrane antigen. Cancer Res. 58, 4055-4060 (1998
85. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of 90Ylabeled anti-PSMA monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531 (2004
86. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23, 4591-4601 (2005
87. Tagawa ST, Milowsky MI, Morris M et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 19(18), 5182-5191 (2013
88. Pandit-Taskar N, O'Donoghue JA, Beylergil V et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 41, 2093-2105 (2014
89. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61(1), 12-25 (2004
90. Friedrich M, Raum T, Lutterbuese R et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY 2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol. Cancer Ther. 11(12), 2664-2673 (2012
91. Petrylak DP, Kantoff PW, Frank RC et al. Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A Phase I trial in taxane-refractory prostate cancer. J. Clin. Oncol. 29(5), Abst 4650 (2011
92. Petrylak DP, Smith DC, Appleman LJ et al. A Phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 32(4), Abstract 83 (2014
93. Viola-Villegas NT, Sevak KK, Carlin SD et al. Noninvasive imaging of PSMA in prostate tumors with 89Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol. Pharm. 11(11), 3965-3973 (2014
94. Jackson PF, Cole DC, Slusher BS et al. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem. 39, 619-622 (1996
95. Kozikowski AP, Nan F, Conti P et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NALADase). J. Med. Chem. 44, 298-301 (2001
96. Foss CA, Mease RC, Fan H et al. Radiolabeled small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res. 11, 4022-402 (2005
97. Cho SY, Gage KL, Mease RC et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 53(12), 1883-1891 (2012
98. Maresca KP, Hillier SM, Femia FJ et al. A series of halogenated heterodimeric inhibitors of prostatespecific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem 52, 347-357 (2009
99. Hillier SM, Maresca KP, Femia FJ et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 69(17), 6932-6940 (2009
100. Barrett JA, Coleman RE, Goldsmith SJ et al. First-in-man evaluation of two high-affinity PSMA-avid small molecules for imaging prostate cancer. J. Nucl. Med. 54(3), 380-387 (2013
101. Hillier SM, Kern AM, Maresca KP et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J. Nucl. Med. 52, 1087-1093 (2011
102. Vallabhajosula S, Nikolopoulou A, Babich JW et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J. Nucl. Med. 55, 1-8 (2014
103. A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology. http://clinicaltrials.gov/show/NCT01667536
104. Zechmann CM, Afshar-Oromieh A, Armor T et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 41(7), 1280-1292 (2014
105. Eder M, Schäfer M, Bauder-Wüst U et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug. Chem. 23(4), 688-697 (2012
106. Eder M, Neels O, Müller M et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: A new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7(7), 779-796 (2014
107. Afshar-Oromieh A, Malcher A, Eder M et al. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J. Nucl. Med. Mol. Imaging. 40(5), 797-798 (2013
108. Afshar-Oromieh A, Zechmann CM, Malcher A et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J. Nucl. Med. Mol. Imaging. 41(1), 11-20 (2014
109. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15(2), 167-172 (2009
110. Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74(6), 659-668 (2014).
111. Chen Z1, Penet MF, Nimmagadda S et al. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano. 6(9), 7752-7762 (2012)
112. Audet M, Bouvier M. Restructuring G-protein-coupled receptor activation. Cell 151(1), 14-23 (2012
113. Mustain WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr. Opin. Endocrinol. Diabetes Obes. 18(1), 75-82 (2011
114. Mazella J, Vincent JP. Functional roles of the NTS2 and NTS3 receptors. Peptides. 27(10), 2469-2475 (2006
115. Wu Z, Martinez-Fong D, Trédaniel J, Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front. Endocrinol. 3, 184 (2013
116. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr. Opin. Endocrinol. Diabetes Obes. 15(1), 58-64 (2008
117. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59(5), 1152-1159 (1999
118. Beer M, Montani M, Gerhardt J et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate 72(3), 318-325 (2012)
119. Ananias HJ, Van den Heuvel MC, Helfrich W, De Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69(10), 1101-1108 (2009
120. Kähkönen E, Jambor I, Kemppainen J et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin. Cancer Res. 19(19), 5434-5443 (2013
121. Wieser G, Mansi R, Grosu AL et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist - from mice to men. Theranostics 4(4), 412-419 (2014
122. Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc. Natl Acad. Sci. USA 91(11), 4673-4677 (1994
123. Valerie NC, Casarez EV, Dasilva JO et al. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 71(21), 6817-6826 (2011)
124. Buchegger F, Bonvin F, Kosinski M et al. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J. Nucl. Med. 44(10), 1649-1654 (2003